4D Molecular Therapeutics secures an $85 million upfront deal with Otsuka, funding its Phase 3 4D‑150 trial for wet AMD and DME and unlocking up to $336 million in milestones and royalties in the Asia‑Pacific market.

4D Molecular Therapeutics Inc is a biopharmaceutical company making strides in developing groundbreaking therapies for genetic diseases, despite facing industry challenges and financial volatility.

4D Molecular Therapeutics Inc. saw a significant surge in its stock price after releasing positive clinical trial results for its diabetic macular edema treatment.

Shares of 4D Molecular Therapeutics surged 26% to $5.69 after the company announced positive results from a clinical trial of its treatment for diabetic macular edema.

4D Molecular Therapeutics, Inc. is a pioneering biopharmaceutical company dedicated to developing innovative therapies for genetic diseases, offering hope and healing to patients worldwide.

4D Molecular Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for genetic diseases, with a global presence and potential for long-term growth.

4D Molecular Therapeutics has received FDA RMAT designation for its drug candidate 4D-150, a potential treatment for Diabetic Macular Edema, which could expedite its development and review.